Search Results
Aug 10, 2026, 09:00 ET RxBenefits Releases Pharmacy Benefits Market Report to Help Benefits Advisors Evaluate Transparent PBMs
concentrated in a small share of claims. Fewer than 2% of prescription claims account for more than 50% of total pharmacy spend, and a single specialty drug can add more than $250,000 per year to plan costs. GLP-1 medications illustrate the pressure: national spending on these drugs rose more
More news about: RxBenefits
Aug 10, 2026, 08:30 ET Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
consideration under the CVR Agreement contemplated in connection with the proposed transaction will become payable, if at all, the risks inherent in the drug development process, including whether the development of the compound subject to the CVR Agreement contemplated in connection with the proposed transaction
More news about: Theravance Biopharma, Inc.
Aug 10, 2026, 08:26 ET Berger Montague PC Investigating Claims on Behalf of Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors After Class Action Filing
suffering from Duchenne's muscular dystrophy.As the lawsuit alleges, on July 27, 2026, before the market opened, the U.S. Food and Drug Administration ("FDA") released briefing documents ahead of its July 29 advisory committee ("AdCom") meeting for the biologics license application ("BLA")
More news about: Berger Montague
Aug 10, 2026, 08:22 ET CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadline
allegedly failed to disclose that they adopted changes to the pre-specified statistical analysis plan (SAP) without agreement from the U.S. Food and Drug Administration (FDA) prior to resubmitting its Biologics License Application (BLA).The HOPE-3 Trial Breakthrough and Subsequent Capital RaiseOn
More news about: Hagens Berman Sobol Shapiro LLP
Aug 10, 2026, 08:01 ET Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics
Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).Acurx's lead product candidate,
More news about: Acurx Pharmaceuticals, Inc.
Aug 10, 2026, 08:00 ET Acarix Receives Regulatory Approval for the CADScor® System in the UAE (United Arab Emirates)
2026 /PRNewswire/ -- Acarix AB (publ) today announced that the CADScor® System has received regulatory approval from the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP), clearing the way for commercial availability of the technology across the United
More news about: Acarix
Aug 10, 2026, 07:30 ET Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
ongoing Phase 1b/2a KYRON trial is designed to serve as the registrational study to support a new drug application submission in the U.S. In addition to having FDA Fast Track, Rare Pediatric Disease and Orphan Drug Product designations, ABS-1230 was accepted into the FDA's new Rare Disease Evidence Principles
More news about: Jazz Pharmaceuticals plc
Aug 10, 2026, 07:00 ET Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
potentially first-in-class drug candidate which targets three validated targets of amylin receptor, GLP-1R and GIPR.-ASC36 is a potentially first-in-class once-monthly to once-quarterly SQ injection which targets amylin receptor.-Investigational New Drug (IND) Applications for
More news about: Ascletis Pharma Inc.
Aug 10, 2026, 07:00 ET Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's
More news about: Labcorp
Aug 10, 2026, 07:00 ET 歌禮宣布在美國啟動兩項治療肥胖症的I期研究：胰澱素受體激動劑多肽月注射劑ASC36、ASC36和GLP-1R/GIPR激動劑多肽ASC35的復方月注射劑ASC36_35FDC
歌禮制藥有限公司是一家全價值鏈整合型生物技術公司，聚焦有望成為治療代謝疾病同類最佳（best-in-class）和同類首創（first-in-class）藥物的開發和商業化。利用公司專有的基於結構的AI輔助藥物發現（Artificial Intelligence-assisted Structure-Based Drug Discovery，AISBDD）、超長效藥物開發平台（Ultra-Long-Acting Platform，ULAP）技術以及口服多肽遞送增強技術（Peptide Oral Transport ENhancement Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥
More news about: 歌禮製藥有限公司
Aug 10, 2026, 07:00 ET Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
clinical data generated by Hansoh outside the United States may not be replicated in the Company's own clinical trials or accepted by the U.S. Food and Drug Administration; risks related to the Company's ability to obtain, maintain, protect and enforce its intellectual property rights, including the scope,
More news about: Avere Therapeutics
Aug 10, 2026, 05:58 ET Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.If you are a shareholder
More news about: DJS Law Group LLP
Aug 10, 2026, 02:36 ET Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
common subtype in CTCL.The program has received Fast Track designation from the FDA, PRIME designation from the EMA for Sézary syndrome, Orphan Drug designation in both the U.S. and EU for CTCL, and Breakthrough Therapy Designation from the FDA for relapsed or refractory Sézary syndrome. The program
More news about: Swedish Orphan Biovitrum AB
Aug 10, 2026, 02:32 ET Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
common subtype in CTCL.The program has received Fast Track designation from the FDA, PRIME designation from the EMA for Sézary syndrome, Orphan Drug designation in both the U.S. and EU for CTCL, and Breakthrough Therapy Designation from the FDA for relapsed or refractory Sézary syndrome. The program
More news about: Swedish Orphan Biovitrum AB
Aug 10, 2026, 00:05 ET Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), in combination with ivonescimab (the Company's PD-1/VEGF bispecific antibody), for the treatment of advanced breast cancer. This
More news about: Akeso, Inc.
Aug 09, 2026, 22:26 ET HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology
opportunity to evaluate these discoveries in the context of defined therapeutic mechanisms and active drug-development programs. By combining patient-derived research and multi-omics analysis with HanchorBio's drug-development capabilities, we aim to shorten the path from scientific discovery to biomarkers,
More news about: HanchorBio Inc.
Aug 09, 2026, 20:00 ET Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
* In this new release, "China" refers to Mainland China market.Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).Ramucirumab Injection (Cyramza®), Selpercatinib Capsules (Retsevmo
More news about: Innovent Biologics
Aug 08, 2026, 05:16 ET Mahamandleshwar Gita Manishi Swami Shri Gyananand Ji Maharaj Enlightens Chandigarh University Students with Timeless Teachings of Bhagavad Gita
responsibility or discipline, is harmful. It won't earn you respect. Freedom is a good thing, but if freedom is leading a person towards pub culture, drug addiction or wrong circle of friends, then it is a bad thing. Therefore, embrace freedom, but keep your focus on responsibility," he said.Answering
More news about: Chandigarh University
Aug 08, 2026, 03:46 ET RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
company pioneering fully engineered circular RNA (circRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for RXIM002. RXIM002 is the world's first circular RNA-based in vivo CAR-T therapy delivered
More news about: RiboX Therapeutics Ltd.
Aug 07, 2026, 22:00 ET Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR
to disclose material information during the Class Period, violating federal securities laws. On July 27, 2026, pre-market, the U.S. Food and Drug Administration ("FDA") published briefing documents ahead of its July 29 advisory committee meeting to review the Biologics License Application ("BLA")
More news about: ClaimsFiler
Aug 07, 2026, 18:23 ET NASDAQ: MDLN Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm
the Reuters article states that according to the FDA, Medline "failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices."Why Did Medline's Stock Drop?Following the news of Medline's FDA
More news about: Kessler Topaz Meltzer & Check, LLP
Aug 07, 2026, 15:42 ET Happiest Baby Announces Voluntary Recall for Extra-Small and Extra-Large SNOO Sack Accessories
Baby announced a voluntary recall of its extra-small (XS) and extra-large (XL) SNOO Sacks®. This action follows a communication from the U.S. Food and Drug Administration (FDA), advising Happiest Baby that the Company needed to obtain FDA's premarket authorization for those two sizes. Out of an abundance
More news about: Happiest Baby, Inc.
Aug 07, 2026, 14:20 ET Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species
of Negasunt Powder under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner. Federal law prohibits the extra-label use of this drug. Additional Important Safety Information Not
More news about: Elanco Animal Health
Aug 07, 2026, 11:05 ET GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23, 2026 to review
More news about: GRAIL, Inc.
Aug 07, 2026, 10:15 ET Anatomic Pathology Market worth $14.5 billion by 2031 - Exclusive Report by MarketsandMarkets™
Digital Pathology Market by Product (Brightfield Scanner, Enterprise Software, Storage System), Application (Teleconsultation, Disease Diagnosis, Drug Discovery), Indication (Onco, Hemo), End User (Pharma & Biotech, Hospital) Al- Global Forecast to 2031About MarketsandMarkets™MarketsandMarkets™
More news about: MarketsandMarkets